– UK, Cambridge – Broken String Biosciences, a genomics company enabling the development of the next generation of more precise, safe, and effective cell and gene therapies, announced the appointments to its Board of Directors of Dr. Laurence Reid (Ph.D.) as Chairman, and Brad Crutchfield as a Non-Executive Director.
About Dr. Laurence Reid
Dr. Laurence Reid is a seasoned biotech entrepreneur with a track record of leadership and company-building success within the sector, previously CEO at Decibel Therapeutics (acquired by Regeneron Pharmaceuticals) and Warp Drive Bio (merged with Revolution Medicines). He served as entrepreneur in residence at Third Rock Ventures, focused on novel drug discovery and development opportunities. Prior to this, he held C-level executive positions at Alnylam Pharmaceuticals, Ensemble Discovery and Millennium Pharmaceuticals. Laurence now applies his expertise in an advisory capacity, serving on the boards of a number of biotech companies. He is also a board member at The Possible Zone and an advisor to Life Science Cares and Mount Auburn Hospital.
Dr. Laurence Reid said: “The promise of therapies based on genome editing is fundamentally linked to understanding the desired genome modifications relative to the undesired modifications. INDUCE-seq is an extremely promising technology that will enable therapeutic developers to bring their cutting-edge treatments to market with a new standard of precision. I’m pleased to be joining the Company and eager to work closely with the leadership team to develop a comprehensive commercial strategy and support the Company in its ongoing growth.”
About Brad Crutchfield
Brad Crutchfield brings nearly 40 years’ experience in the development and commercialization of life science tools to Broken String’s Board. Most recently, he served as CCO of 10x Genomics, building the global sales and support organization that today drives over $600 million in business, and working closely with the CEO to support the Company through its IPO in 2019. Previously, Brad has held several leadership positions, including as SVP of Life Sciences at QIAGEN, VP and GM EMEA at Illumina, and President of the Life Science Group at Bio-Rad Laboratories. He currently sits on the Boards of Pixelgen AB, Partillion Inc and S2 Genomics, in addition to serving as Senior Advisor for Alamar Biosciences.
Brad Crutchfield commented: “Cell and gene therapies hold immense promise for transforming disease treatment, and Broken String’s solution will be instrumental in helping companies accelerate and de-risk their drug development pipelines. By enabling the development of these next-generation therapies with precision and safety, we can enhance enterprise value for pharma and biotech firms. I look forward to leveraging my experience in bringing innovative life science tools to market to help position the company’s offerings for success in this rapidly evolving field.”
For more information : https://www.brokenstringbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.